192 related articles for article (PubMed ID: 38292925)
1. Efficacy and safety of neoadjuvant immunotherapy protocols and cycles for non-small cell lung cancer: a systematic review and meta-analysis.
Wang H; Liang S; Yu Y; Han Y
Front Oncol; 2024; 14():1276549. PubMed ID: 38292925
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant immunotherapy or chemoimmunotherapy in non-small cell lung cancer: a systematic review and meta-analysis.
Jiang J; Wang Y; Gao Y; Sugimura H; Minervini F; Uchino J; Halmos B; Yendamuri S; Velotta JB; Li M
Transl Lung Cancer Res; 2022 Feb; 11(2):277-294. PubMed ID: 35280319
[TBL] [Abstract][Full Text] [Related]
3. A systematic review and meta-analysis of neoadjuvant chemoimmunotherapy in stage III non-small cell lung cancer.
Liu W; Zhang T; Zhang Q; Li L; Xu C
BMC Pulm Med; 2022 Dec; 22(1):490. PubMed ID: 36582007
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Neoadjuvant Chemoimmunotherapy in Resectable Esophageal Squamous Cell Carcinoma: A Meta-analysis.
Xu J; Yan C; Li Z; Cao Y; Duan H; Ke S
Ann Surg Oncol; 2023 Mar; 30(3):1597-1613. PubMed ID: 36380254
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of neoadjuvant immunotherapy combined with chemoradiotherapy or chemotherapy in esophageal cancer: A systematic review and meta-analysis.
Liu Y; Bao Y; Yang X; Sun S; Yuan M; Ma Z; Zhang W; Zhai Y; Wang Y; Men Y; Qin J; Xue L; Wang J; Hui Z
Front Immunol; 2023; 14():1117448. PubMed ID: 36761760
[TBL] [Abstract][Full Text] [Related]
6. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, safety, and survival of neoadjuvant immunochemotherapy in operable non-small cell lung cancer: a systematic review and meta-analysis.
Zheng Y; Feng B; Chen J; You L
Front Immunol; 2023; 14():1273220. PubMed ID: 38106421
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of neoadjuvant immunotherapy in resectable gastric/gastroesophageal junction tumors: a meta-analysis and systematic review.
Wang J; Tong T; Zhang G; Jin C; Guo H; Liu X; Zhang Z; Li J; Zhao Y
Front Immunol; 2024; 15():1339757. PubMed ID: 38352873
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant immunotherapy improves outcomes for resectable gastroesophageal junction cancer: A systematic review and meta-analysis.
Wu D; Yang L; Yan Y; Jiang Z; Liu Y; Dong P; Lv Y; Zhou S; Qiu Y; Yu X
Cancer Med; 2024 May; 13(9):e7176. PubMed ID: 38716645
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant immunotherapy and chemoimmunotherapy for stage II-III muscle invasive bladder cancer.
Chen H; Yang W; Xue X; Li Y; Jin Z; Ji Z
Front Immunol; 2022; 13():986359. PubMed ID: 36059550
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant Immunotherapy and Non-Small Cell Lung Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Yu S; Zhai S; Gong Q; Xiang C; Gong J; Wu L; Pu X
Am J Clin Oncol; 2023 Nov; 46(11):517-528. PubMed ID: 37749786
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitors in neoadjuvant therapy of non-small cell lung cancer: a systematic review and meta-analysis.
Ge S; Huang C
J Thorac Dis; 2022 Feb; 14(2):333-342. PubMed ID: 35280480
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant Immunotherapy Improves Treatment for Early Resectable Non-Small-Cell Lung Cancer: A Systematic Review and Meta-analysis.
Dong P; Yan Y; Yang L; Wu D; Wang H; Lv Y; Zhang J; Yu X
J Oncol; 2022; 2022():2085267. PubMed ID: 36213828
[TBL] [Abstract][Full Text] [Related]
14. Comparison of neoadjuvant immunotherapy versus routine neoadjuvant therapy for patients with locally advanced esophageal cancer: A systematic review and meta-analysis.
Qin H; Liu F; Zhang Y; Liang Y; Mi Y; Yu F; Xu H; Li K; Lin C; Li L; Tian Z; Wang L
Front Immunol; 2023; 14():1108213. PubMed ID: 37033991
[TBL] [Abstract][Full Text] [Related]
15. [Application of Neoadjuvant Chemoimmunotherapy in Resectable NSCLC].
Wang H; Han Y
Zhongguo Fei Ai Za Zhi; 2023 Nov; 26(11):822-832. PubMed ID: 38061884
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in locally advanced esophageal cancer: A meta-analysis.
Wang J; Zhang K; Liu T; Song Y; Hua P; Chen S; Li J; Liu Y; Zhao Y
Front Oncol; 2022; 12():974684. PubMed ID: 36158679
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of neoadjuvant immunotherapy for non-metastatic colorectal cancer.
Zhou L; Yang XQ; Zhao GY; Wang FJ; Liu X
Front Immunol; 2023; 14():1044353. PubMed ID: 36776899
[TBL] [Abstract][Full Text] [Related]
18. Analysis of treatment-related adverse events and wound complications of surgical resection after neoadjuvant chemoimmunotherapy for non-small cell lung cancer.
Li Y; Hu X; Zhang R; Wu N; Xia Q; Gu P
Int Wound J; 2024 Mar; 21(3):e14831. PubMed ID: 38484730
[TBL] [Abstract][Full Text] [Related]
19. Short-term outcome of neoadjuvant immunotherapy and chemotherapy in non-small cell lung cancer: A systematic review and meta-analysis.
Zhang C; Hong HZ; Wu YL; Zhong WZ
JTCVS Open; 2021 Dec; 8():588-607. PubMed ID: 36004199
[TBL] [Abstract][Full Text] [Related]
20. Comparison of neoadjuvant chemoimmunotherapy and chemotherapy alone for resectable stage III non-small cell lung cancer: a real-world cohort study.
Zhou S; Liu Y; Liu K; Zhang J; Liang H; Wu Y; Ye H; Liang Y; Zhang J; Huang W
Front Immunol; 2023; 14():1343504. PubMed ID: 38187385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
